Roupen Odabashian shared a post by OncoDaily on LinkedIn, adding:

“This was a great interview on OncoDaily with Dr. Mikkael Sekeres.
Dr. Sekeres is the Chief of the Division of Hematology at the University of Miami Health System and Sylvester Comprehensive Cancer Center. He chaired the Oncology Drugs Advisory Committee of the FDA, has served on the editorial boards of several medical journals, and chairs scientific advisory boards for patient advocacy groups and research funding agencies.

Together, we discussed FDA drug approvals and offered advice for early-career oncologists who are looking for a similar path.”

Quoting OncoDaily’s post:

“Oncodaily Dialogues No.8 Mikkael Sekeres/ Hosted by Roupen Odabashian”

Source: Roupen Odabashian/LinkedIn and OncoDaily/LinkedIn

Dr. Roupen Odabashian is an accomplished Internal Medicine Physician and Hematology/Oncology Fellow with a profound commitment to advancing healthcare through clinical practice, research, and technology. Currently based at the prestigious Karmanos Cancer Institute, Dr. Odabashian is actively involved in pioneering cancer treatments and conducting clinical research.

In addition to his clinical work, Dr. Odabashian is a multifaceted healthcare professional. He hosts podcast at OncoDaily, engaging with leading experts in oncology to share valuable insights with the medical community. Dr. Odabashian also contributes his expertise as an advisor at Spiraldot Health and Mesh AI, supporting innovative ventures in healthcare technology and collaborative scheduling to combat clinician burnout. With his diverse roles and unwavering dedication, Dr. Odabashian exemplifies a commitment to driving positive change in healthcare.